The CHMP2B antibody is a crucial tool for studying charged multivesicular body protein 2B (CHMP2B), a component of the endosomal sorting complex required for transport (ESCRT)-III. CHMP2B plays a key role in membrane remodeling processes, including endosomal sorting, cytokinesis, and autophagy. It facilitates the formation of multivesicular bodies (MVBs) by recruiting ESCRT-III subunits to coordinate vesicle scission and cargo sorting. Research on CHMP2B gained prominence due to its association with neurodegenerative diseases. Mutations in the CHMP2B gene (e.g., p.Thr104Asn) are linked to rare autosomal-dominant forms of frontotemporal dementia (FTD-3) and amyotrophic lateral sclerosis (ALS). These mutations disrupt ESCRT-III function, leading to abnormal endosomal-lysosomal trafficking, protein aggregation, and neuronal degeneration. CHMP2B antibodies are widely used in immunoassays (e.g., Western blot, immunohistochemistry) to detect CHMP2B expression, localization, and pathological aggregates in cellular and tissue models. They also help investigate disease mechanisms, such as impaired autophagy or lysosomal dysfunction in neurodegeneration. Additionally, CHMP2B antibodies aid in exploring broader ESCRT-III roles in viral budding, cell division, and membrane repair. Their specificity and reliability make them essential for both basic research and translational studies targeting ESCRT-related disorders.